Premium
Artificial Liver: The Effect of ACAC Microencapsulated Charcoal Hemoperfusion on Fulminant Hepatic Failure
Author(s) -
Chirito E.,
Reiter B.,
Lister C.,
Chang T. M. S.
Publication year - 1977
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.1977.tb00972.x
Subject(s) - hemoperfusion , fulminant hepatic failure , charcoal , artificial liver , activated charcoal , liver failure , chemistry , medicine , pharmacology , gastroenterology , liver transplantation , organic chemistry , transplantation , adsorption , hemodialysis
Control trials and statistical analysis were carried out to assess the effects of albumin‐collodion microencapsulated activated charcoal (ACAC) hemoperfusion on fulminant hepatic coma. A rat model of galactosamine induced fulminant hepatic coma was used. Rats which did not recover died at 3.0 0.6 days after galactosamine injection. Those which survived this period recovered. Forty‐eight hours after galactosamine injection, a test group of 21 rats were treated with 1 hour hemoperfusion and compared with an untreated group of 23 rats. 71.4% of the treated group survived as compared to 30.4% of the untreated rats. Statistical analysis (t test) shows a significant increase in recovery for the treated group (<0.01). Biochemical and histological results will be discussed.